

development and

April 8, 1959, by Diane Villax and two other shareholders, Horthy and Onody. Their surnames' first syllables joined together result in Hovione's name. By 1963, the Villaxes acquire sole ownership of the company. The first products to be manufactured,

in a home laboratory.



Thanks to hard work, good luck and his patents, Ivan Villax becomes the technical director and a shareholder in an Italian company. Upon its sale, he capital for Hovione's irst industrial plant, in oures, which starts to



This Financial Times re-investment, the article, from 1982, is the first time Hovione aets grow and increase the media's attention. its manufacturing The author focuses on the unlikely However Villax is keen combination of to expand into the a family business Far-East and build and cutting edge technology.





enters a European Union Environment in Industry. in the recovery of waste

Hovione's 500th patent is granted and the company starts to

In 2008, we acquire a new industrial site, in Taizhou, south of Shanghai, where contrast media is produced - it becomes the largest producer of generic

Hovione develops an

inhaler, TwinCaps®.

influenza scare in

Inavir TwinCaps® is

approved in 2010 in

Japan and reaches a

40% market share.

2005.

specially for the avian

to treat the causes of cystic fibrosis. It is also the first genotype specific dru approval, developed under full QbD.

Ivacaftor is approved

Over the next decade

we will produce the

new drug approvals

vast majority of

for spray-dried

dispersions (SDDs).



In Sete Casas we open a Drug Product Center. This allows us to formulate oral forms and inhaled drugs. Hovione Capital is



Portuguese Ministe

Ivan Villax meet in 1957 and are married in 1958. Their partnership in life and work would last 46 years.









is a crucial market for the Company, Japanese labs approach Hovione because of its process patents in the area of corticosteroids. Tobishi was the main customer at that time.

From early days Japan



Ivan and Diane Villax attend the Canton fair in the Autumn of 1978. Deng Xiaoping has only just reached power but the writing is already on the wall: China has a promising chemical industry manufacturing raw-materials and is good destination for Hovione.



The 1980s are a successful decade in the manufacture and sales of doxycycline. Hovione expands into the US market, supplying this antibiotic to an emergent generics industry. But the decade would also be marked by intense patent litigation between Pfizer and Hovione concerning the homogenous catalysis final step. The controversy around the role of Villax's rhodium catalyst, pictured here, would lead to a collaboration with Nobel laureate Sir Geoffrey Wilkinson, and after 10 years the matter was







incorporated and a contract is signed with the Macau government securing a 25-year concession for a plot of Construction begins in 1985 and the plant starts to operate in December 1986. The first FDA

inspection takes place in



In 1990, after 42 years of absence, Villax returns to Hungary. His alma mater, the Technical University of Budapest awards him a doctorate after evaluating his scientific curriculum. He would later say this was one of the happiest days

From 1995 onwards,

Ivan Villax begins

handing over his



In 2000, in New

Jersey we build

Transfer Centre.

commitment to

Hovione's Technology

serving the US pharma innovators.

explore other IP

technology.

avenues in inhalation



We acquire Pfizer's

Ireland, the deal is

signed on Hovione's

This becomes Hovione's

volume, validated API

production for innovator

premier site for high

50th anniversary.

pharmaceutical



to operate in a safe manner, the diversity of a team that constantly strives to learn, but more than anything else it refers to the kind of commitment every client gets from each one of us.

In It for IIfe becomes

our increasing

actively building a

our motto. This reflects

contribution to patients'

lives, the imperative of

quality culture, the need

Our commitment to PAT and automation, our pragmatic approach to compliance, our desire to processes lead us to make bold steps into continuous chemistry and formulation.

Our 9°W Program starts

establishing partnerships

We installed an analytical

chemistry lab that runs

our LIMS, our specs and

our methods in ISEL.

a vocational training

funding students and

with Academia.



As from 2014 we

than 4 new drug

each year.

stand behind no less

approvals by FDA in

We believe that the

number of approvals

will grow and we are

investing to continue

to be part of this

success.















from Sete Casas to

development and

Lumiar, This 7,600m²

state-of-the-art lab has

230 scientists focusing